Novo, Nordisks

Novo Nordisk's CagriSema Filing Heads for Q4 2026 FDA Verdict as EU Clears Frehemgo

Published on 11/21/2026 at 20:31 | Editorial boerse-global.de
Novo Nordisk expects a Q4 2026 FDA decision on CagriSema as REDEFINE data show up to 25.4% weight loss; EU approves Frehemgo for haemophilia A.
Novo, Nordisks, CagriSema, Filing, Heads, FDA, Verdict, Clears, Frehemgo, Nordisk Illustration mit AI erstellt.

Novo Nordisk has a US regulatory decision to look forward to on its investigational CagriSema, with the Danish drugmaker expecting the Food and Drug Administration to rule on the already-submitted application in the fourth quarter of 2026. The timeline emerged alongside a batch of pipeline updates, a fresh EU approval and the latest leg of the company's share buyback.

On the pipeline front, a post-hoc analysis of the REDEFINE 1 trial showed patients who responded early to CagriSema shed an average of 25.4% of their body weight by week 68. Data from REDEFINE 9, released on 14 November, put estimated mean weight loss at 20.7% and 21.0% for the two lower doses, against 2.0% in the placebo arm. Those estimates assume participants stayed on their assigned treatment for the full 68 weeks.

Novo Nordisk also looked at bone-health biomarkers among amylin-based agents. According to the company, CagriSema and Cagrilintid reduced bone loss in a preclinical model. Separately, Reuters reported real-world data on the once-daily Wegovy pill: patients who kept taking it lost an average of 6.2% of their body weight within three months.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Brussels Gives Frehemgo the Green Light

In Brussels, the European Commission granted EU approval to Frehemgo (Denecimig) on 13 November for the treatment of haemophilia A. The therapy can be given monthly, every two weeks or weekly.

The regulatory win and the CagriSema readouts came in a week when Novo Nordisk was also busy on the research and capital-return fronts. Analytics firm nference announced a partnership with the company on Wednesday, combining Novo Nordisk's clinical trial data with nference's artificial intelligence technology and health data network to study cardiovascular and metabolic disease.

Buyback Passes 43.7 Million Shares

Novo Nordisk said on 16 November that it had repurchased roughly 43.7 million B shares for about DKK 12.1 billion under its current programme through 13 November.

The shares came under pressure in the prior session, closing 3.0% lower at EUR 34.44, as AI-related stocks led a broad pullback on US markets, according to the AP news agency.

Ad

Novo Nordisk Stock: New Analysis - 21 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70543388 |